Vor Biopharma Inc. (NASDAQ:VOR) Stock Has Consensus Target Price of $38.00

Vor Biopharma Inc. (NASDAQ:VOR) has received a consensus recommendation of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat reports. Three analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. The average twelve-month target price among brokers that have covered the stock in the last year is $38.00.

VOR has been the topic of several research reports. Weiss Ratings upgraded Vor Biopharma from a “sell (d+)” rating to a “hold (c-)” rating in a report on Monday, September 14th. Citigroup raised Vor Biopharma to a “strong-buy” rating in a research report on Thursday, October 15th. William Blair assumed coverage on Vor Biopharma in a report on Wednesday, October 21st. They issued an “outperform” rating for the company. Wedbush increased their price target on Vor Biopharma from $18.00 to $27.00 and gave the stock a “neutral” rating in a research report on Wednesday, August 12th. Finally, Wall Street Zen upgraded Vor Biopharma from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th.

Institutional Trading of Vor Biopharma

A number of hedge funds have recently added to or reduced their stakes in the business. Braidwell LP grew its holdings in Vor Biopharma by 22.8% during the 2nd quarter. Braidwell LP now owns 573,104 shares of the company’s stock worth $10,551,000 after acquiring an additional 106,330 shares in the last quarter. Renaissance Technologies LLC bought a new stake in shares of Vor Biopharma in the 1st quarter valued at about $2,298,000. Bank of America Corp DE raised its holdings in shares of Vor Biopharma by 28,408.1% in the 1st quarter. Bank of America Corp DE now owns 112,892 shares of the company’s stock valued at $2,014,000 after purchasing an additional 112,496 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Vor Biopharma in the 2nd quarter valued at about $1,799,000. Finally, Simplify Asset Management Inc. purchased a new stake in shares of Vor Biopharma in the 1st quarter worth approximately $955,000. 97.29% of the stock is owned by hedge funds and other institutional investors.

Vor Biopharma Stock Performance

Shares of NASDAQ:VOR opened at $18.26 on Friday. Vor Biopharma has a 1 year low of $6.50 and a 1 year high of $28.66. The business has a 50 day simple moving average of $21.13 and a two-hundred day simple moving average of $18.44.

Vor Biopharma (NASDAQ:VOR) last released its earnings results on Tuesday, August 11th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.11). As a group, equities research analysts predict that Vor Biopharma will post -2.56 EPS for the current fiscal year.

Vor Biopharma Company Profile

Vor Biopharma Inc is a clinical-stage biotechnology company focused on developing engineered hematopoietic stem cell therapies for the treatment of cancer, particularly blood cancers. The company combines gene-editing technologies with targeted immunotherapies to address limitations associated with conventional cancer treatments.

Vor’s platform is designed to create engineered hematopoietic stem cells that can protect healthy blood-forming cells from targeted therapies. Its lead program, VOR33, is an investigational CD33-edited hematopoietic stem cell therapy intended to support the use of CD33-targeted treatments in patients with acute myeloid leukemia.